ERBB2 and breast carcinoma: Targeted inhibition of oncogenic kinases is a promising therapeutic option in several molecularly defined contexts, and mAb-based targeting of the Her2 oncogene in breast cancers has dramatically changed the outcome of this subclass of the disease.